At a glance
- Originator Kaneka
- Developer Kanegafuchi Chemicals; Kaneka
- Class Antihyperlipidaemics; Antineoplastics; Nootropics
- Mechanism of Action Protein tyrosine kinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Atherosclerosis; Coronary artery restenosis